Literature DB >> 23771951

Hepatitis B reactivation following treatment with abatacept in a patient with past hepatitis B virus infection.

Antonis Fanouriakis1, Dimitrios Vassilopoulos, Argyro Repa, Dimitrios T Boumpas, Prodromos Sidiropoulos.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23771951     DOI： 10.1093/rheumatology/ket221

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  9 in total

Review 1.  Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions.

Authors:  Rohit Loomba; T Jake Liang
Journal:  Gastroenterology       Date:  2017-02-20       Impact factor: 22.682

Review 2.  Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies.

Authors:  Joshua S Davis; David Ferreira; Emma Paige; Craig Gedye; Michael Boyle
Journal:  Clin Microbiol Rev       Date:  2020-06-10       Impact factor: 26.132

Review 3.  Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations.

Authors:  Shunsuke Mori; Shigetoshi Fujiyama
Journal:  World J Gastroenterol       Date:  2015-09-28       Impact factor: 5.742

4.  Risk of hepatitis B virus reactivation following treatment with abatacept: A retrospective study of international pharmacovigilance databases.

Authors:  Jingjing Wang; Xin Zhang; Xiaozhen Geng; Juanjuan Shi; Xiaoli Jia; Shuangsuo Dang; Wenjun Wang
Journal:  EClinicalMedicine       Date:  2022-05-05

Review 5.  Reactivation of occult hepatitis B virus infection in patients with rheumatic diseases: pathogenesis, risk assessment and prevention.

Authors:  Masaru Kato; Tatsuya Atsumi
Journal:  Rheumatol Int       Date:  2015-11-16       Impact factor: 2.631

Review 6.  Prevention of Hepatitis B reactivation in the setting of immunosuppression.

Authors:  Venessa Pattullo
Journal:  Clin Mol Hepatol       Date:  2016-06-13

Review 7.  New pharmacological strategies in rheumatic diseases.

Authors:  R E Schiotis; A D Buzoianu; D F Mureșanu; S Suciu
Journal:  J Med Life       Date:  2016 Jul-Sep

8.  Reactivation of occult hepatitis B virus infection under treatment with abatacept: a case report.

Authors:  Rossella Talotta; Fabiola Atzeni; Piercarlo Sarzi Puttini
Journal:  BMC Pharmacol Toxicol       Date:  2016-04-21       Impact factor: 2.483

Review 9.  Reactivation of hepatitis B virus infection in rheumatic diseases: risk and management considerations.

Authors:  Christos Koutsianas; Konstantinos Thomas; Dimitrios Vassilopoulos
Journal:  Ther Adv Musculoskelet Dis       Date:  2020-03-16       Impact factor: 5.346
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.